

vaccine safety and adverse reactions to vaccines.

Matters to be Discussed: The Subcommittee will discuss the inclusion of influenza and pneumococcal vaccines in the National Vaccine Injury Compensation Program summation, direction and closure; focus of safety subcommittees; and a review of report and recommendations from the Task Force on Safer Childhood Vaccines.

Name: NVAC Subcommittee on Immunization Coverage.

Time and Date: 1:30 p.m.–5 p.m., September 9, 1996.

Place: Hubert H. Humphrey Building, Room 423A, 200 Independence Avenue, SW, Washington, DC 20201.

Status: Open to the public, limited only by the space available.

Purpose: This subcommittee will identify and propose solutions that provide a multifaceted and holistic approach to reducing barriers that result in low immunization coverage for children.

Matters to be Discussed: The Subcommittee will discuss the forum on assessment and related immunization issues; the outline for the Subcommittee's report; and the assessment of immunization coverage.

Name: NVAC Subcommittee on Future Vaccines.

Time and Date: 1:30 p.m.–5 p.m., September 9, 1996.

Place: Hubert H. Humphrey Building, Room 405A, 200 Independence Avenue, SW, Washington, DC 20201.

Status: Open to the public, limited only by the space available.

Purpose: This subcommittee will develop policy options and guide the National Vaccine Program activities which will lead to development, licensure, and best use of new and existing vaccines in the simplest possible immunization schedules.

Matters to be Discussed: The Subcommittee will discuss updates on vaccine procurement strategies, the United States Agency for International Development vaccine research agenda, and a discussion of case studies in vaccine development.

Contact Person for More Information: Felecia D. Pearson, Committee Management Specialist, NVPO, CDC, 1600 Clifton Road, NE, M/S D50, Atlanta, Georgia 30333, telephone 404/639-7250.

This notice is being published less than 15 days prior to the meeting due to the inability to transmit the document electronically.

Dated: August 22, 1996.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 96-21924 Filed 8-27-96; 8:45 am]

BILLING CODE 4163-18-M

Health Resources and Services Administration

Advisory Council; Notice of Establishment

Pursuant to the Federal Advisory Committee Act, Public Law 92-463 (5 U.S.C. Appendix 2), the Secretary, Department of Health and Human Services announces the establishment of the following advisory council.

Designation: Advisory Committee to the Administrator, HRSA.

Purpose: Advises the Secretary of HHS and the Administrator of HRSA on policy matters pertinent to HRSA mission responsibilities in the conduct and support of health care delivery, health workforce, and related programs.

The committee may make recommendations concerning program development, resource allocation, and HRSA administrative practices and policies, and other specific matters which affect the operation of the Agency.

Structure: The Committee shall consist of the Secretary or designee as Chair and 16 members. Eleven members shall be authorities who are knowledgeable in the fields of health care delivery and finance, the health workforce and training of the workforce, public health, and the special needs of disadvantaged populations. Five members shall be representatives of the general public.

Dated: August 22, 1996.

Jackie E. Baum,

Advisory Committee Management Officer, HRSA.

[FR Doc. 96-21919 Filed 8-27-96; 8:45 am]

BILLING CODE 4160-15-P

National Institutes of Health

Notice of Meeting of the National Advisory Council for Human Genome Research

Pursuant to Pub. L. 92-463, notice is hereby given of the meeting of the National Advisory Council for Human Genome Research, National Center for Human Genome Research, September 16-17, 1996, Holiday Inn, Washington/Chevy Chase, Palladian West/Center, 5522 Wisconsin Avenue, Chevy Chase, Maryland.

This meeting will be open to the public on Monday, September 16, from 8:30 to 1:00 p.m. to discuss administrative details or other issues relating to committee activities. Attendance by the public will be limited to space available.

In accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. and sec. 10(d) of Pub. L. 92-463, the meeting will be closed to the public on September 16 from 1:00 p.m. to recess and on September 17 from 8:30 a.m. to adjournment, for the

review, discussion and evaluation of individual grant applications. The applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Dr. Elke Jordan, Deputy Director, National Center for Human Genome Research, National Institutes of Health, Building 31, Room 4B09, Bethesda, Maryland 20892, (301) 496-0844, will furnish the meeting agenda, rosters of Committee members and consultants, and substantive program information upon request.

Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact Ms. Jane Ades, (301) 594-1229, two weeks in advance of the meeting.

(Catalog of Federal Domestic Assistance Program No. 93.172, Human Genome Research)

Dated: August 21, 1996.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 96-21897 Filed 8-27-96; 8:45 am]

BILLING CODE 4140-01-M

National Cancer Institute; Notice of Meetings of the National Cancer Advisory Board and its Subcommittee

Pursuant to Pub. L. 92-463, notice is hereby given of the meeting of the National Cancer Advisory Board, National Cancer Institute, and its Subcommittees on September 10-11, 1996. Except as noted below, the meetings of the Board and its Subcommittees will be open to the public to discuss issues relating to committee business as indicated in the notice. Attendance by the public will be limited to space available.

A portion of the Board meeting will be closed to the public in accordance with the provisions set forth in secs. 552b(c)(4), 552b(c)(6), and 552(c)(9)(B), Title 5, U.S.C. and sec. 10(d) of Pub. L. 92-463, for the review, discussion and evaluation of individual grant applications and for discussion of issues pertaining to programmatic areas and/or NCI personnel, and discussion of subcommittee recommendations regarding NCI staff support to the Board and operating procedures. These applications and discussions could reveal confidential trade secrets or commercial property such as patentable material, and personal information concerning the individuals associated

with the applications or programs, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy and premature disclosure of recommendations which would inhibit the final outcome and subsequent implementation of recommendations.

The Committee Management Office, National Cancer Institute, National Institutes of Health, Executive Plaza North, Room 630E, 9000 Rockville Pike, Bethesda, Maryland 20892 (301/496-5708), will provide summaries of the meetings and rosters of the Board members, upon request.

Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact Ms. Carole Frank, Committee Management Specialist, at 301/496-5708 in advance of the meeting.

Name of Committee: National Cancer Advisory Board.

Contact Person: Dr. Marvin R. Kalt, Executive Secretary, National Cancer Institute, NIH, Executive Plaza North, Room 600A, 6130 Executive Blvd., Bethesda, MD 20892-7405; (301) 496-5147.

Dates of Meeting: September 10-11, 1996.

Place of Meeting: Conference Room 10, Building 31C, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892.

Open: September 10-8 am to approximately 12:15 pm.

Agenda: Director's Report on the National Cancer Institute; NCI Strategic Planning and Evaluation Structure; NCAB: 25th Anniversary Initiatives; New Business; Scientific Presentations; and Report on the Activities of the President's Cancer Panel.

Closed: September 10-2:30 pm to approximately 4:30 pm.

Agenda: For review and discussion of individual grant, applications, and extramural/intramural programmatic, and personnel policies.

Open: September 11-8:30 am to 11 am.

Agenda: Scientific Presentations; Subcommittee Reports; Report on the NCAB Retreat; Peer Review Initiatives; Continuing New Business.

Closed: September 11-11 am to 4:30 pm.

Agenda: Review and evaluation of NCAB staff support, structure and function.

Name of Committee: Subcommittee on Clinical Investigations.

Contact Person: Dr. Robert Wittes, Executive Secretary, National Cancer Institute, NIH, Building 31, Room 3A44, Bethesda, MD 20892; (301) 496-4291.

Date of Meeting: September 10, 1996.

Place of Meeting: Conference Room 7, Building 31C, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892.

Open: 12:30 pm to 1:30 pm.

Agenda: To discuss the By Pass Budget and translational research as well as the possibilities for allocating NCI dollars to defray clinical costs.

Name of Committee: Subcommittee on Planning and Budget.

Contact Person: Ms. Cherie Nichols, Executive Secretary, National Cancer

Institute, NIH, Building 31, Room 11A19, Bethesda, MD 20892; (301) 496-5515.

Date of Meeting: September 10, 1996.

Place of Meeting: Conference Room 9, Building 31C, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892.

Open: 12:30 pm to 1:30 pm.

Agenda: To discuss the NCI budget and various planning issues.

This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

(Catalog of Federal Domestic Assistance Program Numbers: 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control)

Dated: August 22, 1996.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 96-21898 Filed 8-27-96; 8:45 am]

BILLING CODE 4140-01-M

Substance Abuse and Mental Health Services Administration

Center for Substance Abuse Treatment; Notice of Meeting

Pursuant to Pub.L. 92-463, notice is hereby given of a meeting of the Center for Substance Abuse Treatment (CSAT) National Advisory Council to be held in September 1996.

A portion of the meeting will be open and include discussion of the Center's policy issues and current administrative, legislative, and program developments.

The meeting will include the review, discussion, and evaluation of individual grant applications, contract proposals, and discussion of information about the Center's procurement plans. Therefore a portion of the meeting will be closed to the public as determined by the Administrator, SAMHSA, in accordance with Title 5 U.S.C. 552b(c)(3), (4), and (6) and 5 U.S.C. App. 2, § 10(d).

A summary of the meeting and roster of council members may be obtained from: Ms. Joann M. Exline, National Advisory Council, CSAT, Rockwall II Building, Suite 619, 5600 Fishers Lane, Rockville, Maryland 20857, Telephone: (301) 443-8923.

Substantive program information may be obtained from the contact whose name and telephone number is listed below.

Committee Name: Center for Substance Abuse Treatment National Advisory Council

Meeting Dates: September 18, 1996, 9:00 a.m.—5:00 p.m. September 19, 1996, 9:00 a.m.—2:15 p.m.

Place: Holiday Inn, 5520 Wisconsin Avenue, Chase Room, Chevy Chase, Maryland 20856

Type: CLOSED: September 18, 9:00 a.m.—11:00 a.m. OPEN: September 18, 11:15 a.m.—5:00 p.m. September 19, 9:00 a.m.—2:15 p.m.

Contact: Marjorie M. Cashion, Executive Secretary, Telephone: (301) 443-8923, and FAX: (301) 480-6077.

Dated: August 22, 1996.

Jeri Lipov,

Committee Management Officer, Substance Abuse and Mental Health Services Administration.

[FR Doc. 96-21921 Filed 8-27-96; 8:45 am]

BILLING CODE 4162-20-P

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

Office of the Assistant Secretary for Housing-Federal Housing Commissioner; Federally Assisted Low-Income Housing Drug Elimination Announcement of Funding Awards Fiscal Year 1995

[Docket No. FR-3858-N-02]

AGENCY: Office of the Assistant Secretary for Housing - Federal Housing Commissioner, HUD.

ACTION: Announcement of funding awards.

SUMMARY: In accordance with section 102(a)(4)(C) of the Department of Housing and Urban Development Reform Act of 1989, this announcement notifies the public of funding awards made by the Department for the Federally Assisted Low-Income Drug Elimination Grant Program. This announcement contains the names and addresses of the Federally Assisted Low-Income Housing Drug Elimination Program grantees and the amount of the awards.

FOR FURTHER INFORMATION CONTACT: Michael Diggs, Office of Multifamily Housing Asset Management and Disposition, Department of Housing and Urban Development, room 6176, 451 Seventh Street, SW., Washington, DC 20410, telephone (202) 708-0558 (this is not a toll-free number). A telecommunications device for hearing- and speech-impaired individuals (TTY) is available at 1-800-877-8339 (Federal Information Relay Service).

SUPPLEMENTARY INFORMATION: These grants are authorized under Chapter 2, Subtitle C, Title V of the Anti-Drug Abuse Act of 1988 (42 U.S.C. 11901 *et seq.*), as amended by Section 581 of the Cranston-Gonzales National Affordable Housing Act (NAHA) of 1990 (42 U.S.C. 8011). Section 581 of NAHA expanded the Drug Elimination Program to include Federally assisted low-income housing. The Departments of Veterans Affairs and Housing and Urban Development, and Independent